Formation Bio, headquartered in United States, remains privately held in the biotechnology / drug discovery space. Investors last valued the company at $1.7B. No public ticker exists for the company.
1 valuation. The latest, $1.7B post-money, was set by the Series D in Jun 2024.
a16zLEADSSanofiSSequoia
ThriveEEmerson CollectiveSSV Angel GrowthFFPV VenturesFormation Bio in-licenses and acquires clinical-stage drug candidates from pharmaceutical companies, universities and biotech firms, then develops them faster and more efficiently using its own tech-driven, AI-native drug development platform. The company aims to reach value inflection points in a drug's life cycle earlier than industry norms. Formation Bio is based in the United States and was founded in 2016 by CEO Ben Liu, a former Oxford Rhodes Scholar, alongside co-founder Linhao Zhang.
Formation Bio's customers are the pharma and biotech companies handing off already-tested clinical-stage assets for faster development and clinical execution. OpenAI CEO Sam Altman is among the investors who have backed this approach to combining pharma and tech talent.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Formation Bio.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Formation Bio availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Formation Bio included.
Lead investors for each round are in the funding timeline.
The closest biotechnology / drug discovery peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Formation Bio is a private company; its shares do not trade on a public exchange.
The last valuation is $1.7B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
